This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Adding the measurement that post #30 says would settle it.
History of pancreatitis: these compounds can rarely trigger pancreatitis. History of pancreatitis increases relative risk. That is a relative contraindication, not absolute, but requires monitoring.
Same conclusion as the reply above, reached differently, which is mildly reassuring.
Post #29 describes the usual case. This is about the unusual one.
Disordered eating history: appetite suppression can trigger relapse in people with history of anorexia, bulimia, or other eating disorders. This is a relative contraindication requiring specialist input.
An observation about Absolute versus relative contraindications that I cannot explain and am posting anyway, on the principle that unexplained observations are more useful public than private.
Somebody's condition being on a list does not settle the decision, and somebody's condition being absent from one does not either.
I have changed my mind on this once already, so take it as current rather than settled.
On post #32 — agreed on the reasoning, with one qualification.
Where a contraindication is relative rather than absolute, the reasoning usually appears in the assessment report rather than the labelling.
If it helps: the failure mode here is usually boring rather than dramatic.
Right, and stated more narrowly than I would have dared to state it.
Allergy to the specific compound: true allergy is rare but possible. Any prior allergic reaction to the same compound or to structurally similar peptides warrants caution.
That has been true for the cases I have seen and I have not seen many.
Somebody's condition being on a list does not settle the decision, and somebody's condition being absent from one does not either.
Allergy to the specific compound: true allergy is rare but possible. Any prior allergic reaction to the same compound or to structurally similar peptides warrants caution.
Caveat: everything above assumes the paperwork is what it says it is.
Post #41 answers the question as asked. The question underneath it is different.
Trying to state the Absolute versus relative contraindications position in a way that someone who disagrees would recognise as fair, because I do not think the version in this thread passes that test.
Concurrent insulin or sulfonylureas: not an absolute contraindication but requires dose adjustment and close monitoring for hypoglycemia. The combination is used with caution, not avoided.
Everything in post #45 holds. The case it does not cover is the one I have.
What I would tell a new member reading about Absolute versus relative contraindications for the first time: the confident posts are not the reliable ones, and the reliable ones are longer.
Narrowing post #45, because the general version has more than one answer.
The strongest argument against my own position on Absolute versus relative contraindications, stated as well as I can state it, since nobody else has yet.
On post #45 — agreed on the reasoning, with one qualification.
The section of the product information covering special warnings is usually longer and more useful than the contraindications list itself.
Noting that I have skin in this question and have tried to discount for it.
That reframing is the whole thing. The facts I already had.
Taking post #48 at face value and following it one step further.
Interaction-based contraindications are compound-pair specific and are the ones most often generalised incorrectly.
An honest declaration on Absolute versus relative contraindications: I have a prior here and it is strong enough that you should weight what I say downward. Stating it rather than hiding it.
Everything in post #51 holds. The case it does not cover is the one I have.
Reading the contraindications section of the actual product information takes two minutes and answers most questions asked here.
That is all I can say without guessing.
Research-use-only material has no labelling and therefore no contraindications listed, which is not the same as having none.
That distinction has done more work for me than anything else in this category.
Answering the question post #54 raises rather than the one it answers.
Medullary thyroid carcinoma (personal or family history) or multiple endocrine neoplasia type 2: absolute contraindication. The rodent preclinical signal is real enough to exclude this population.
It is worth checking rather than assuming, which costs nothing.
Picking up post #57: that is the part I would want checked first.
Careful with the language on Absolute versus relative contraindications. "Not detected" and "not present" are different findings and the first is a statement about the method.
On post #58 — agreed on the reasoning, with one qualification.
Two questions I would want answered before drawing anything from the Absolute versus relative contraindications data above: how were the cases selected, and what happened to the ones that dropped out.